Elite Pharmaceuticals reported financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 10.4% to $40.1 million. The growth was driven by the company's Elite label amphetamine and naltrexone product lines, leading to a 21% increase in operating income to $9.9 million.
Elite Pharmaceuticals reported net income of $23.2 million for the six months ended September 30, 2026, a significant increase from $7.8 million in the prior year period, largely driven by a $9.8 million gain from the change in fair value of derivative warrants. While six-month revenue slightly decreased to $72.4 million, the company maintained a strong cash position of $34.9 million and significantly reduced its total liabilities from $39.4 million to $22.1 million.
Elite Pharmaceuticals increased its Board of Directors from four to six members and appointed Dr. Aqeel A. Fatmi and John W. LaRocca as new directors. Both appointees bring extensive pharmaceutical industry experience in R&D, operations, and legal governance to the board.
Elite Pharmaceuticals Insider Barry H. Dash Buys $26K of Stock
Barry H. Dash bought 100,000 shares of Elite Pharmaceuticals Inc at $0.2598 a share, worth $26K in total on Oct 9, 2026. Shares held after the trade: 3,365,555 (+3.1%).